Cytokinetics, Incorporated (CYTK) Revenue by Segment & Business Profile
Net Product Revenue was 88.5% of Cytokinetics, Incorporated's revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CYTKCytokinetics, IncorporatedFollow CYTK — free
—
Price chart with a free account
- Market cap
- 8.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What the company does
Cytokinetics, Incorporated is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Net Product Revenue (88%), Collaboration Revenues (12%). Trailing twelve-month revenue: $67.7 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| China | 1M | 2.8% | — |
Cytokinetics, Incorporated — questions
- What does Cytokinetics, Incorporated do?
- Cytokinetics, Incorporated is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Net Product Revenue (88%), Collaboration Revenues (12%). Trailing twelve-month revenue: $67.7 million as of 2026-06-30.
- How does Cytokinetics, Incorporated make money?
- By the lines it reports in its SEC filings: Net Product Revenue 88.5%, Collaboration Revenues 11.5% of revenue.
Every figure on this page comes from Cytokinetics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.